Skip to content
HowShorted

Prestige Consumer Healthcare Inc. short interest in 2025

In 2025, Prestige Consumer Healthcare Inc.'s disclosed short interest ran from 4.72% of shares outstanding on 15 Jan 2025 to 4.23% on 31 Dec 2025, a change of -0.49 percentage points. The year's high was 4.72% on 15 Jan 2025 and its low 2.50% on 15 Aug 2025, averaging 3.40% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 8.03 days on 15 Jan 2025. Full history: Prestige Consumer Healthcare Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Prestige Consumer Healthcare Inc. in 2025

2025 in figures

Start of year
4.72% (15 Jan 2025)
End of year
4.23% (31 Dec 2025)
Change
-0.49 pp
High
4.72% (15 Jan 2025)
Low
2.50% (15 Aug 2025)
Average
3.40%
Highest days to cover
8.03 (15 Jan 2025)
SEC filings marked
8

Every report in 2025

Prestige Consumer Healthcare Inc. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 20254.72%8.03
31 Jan 20254.18%7.77
14 Feb 20253.40%4.1810-Q filed, results (8-K)
28 Feb 20253.07%4.94
14 Mar 20253.10%3.83
31 Mar 20253.18%4.69
15 Apr 20253.35%3.42
30 Apr 20253.20%5.44
15 May 20253.47%3.92results (8-K), 10-K filed
30 May 20253.71%5.13
13 Jun 20253.36%6.32
30 Jun 20253.37%4.06
15 Jul 20253.07%3.22
31 Jul 20252.64%3.26
15 Aug 20252.50%1.9110-Q filed, results (8-K)
29 Aug 20252.88%2.48
15 Sep 20253.14%2.44
30 Sep 20253.20%2.80
15 Oct 20253.35%4.34
31 Oct 20253.15%4.14
14 Nov 20253.28%3.2510-Q filed, results (8-K)
28 Nov 20253.72%4.22
15 Dec 20254.44%4.65
31 Dec 20254.23%4.78

See also: Prestige Consumer Healthcare Inc.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.